Authors: M. Aschermann; J. Horák; V. Řezníček; prof. MUDr. Jan Bělohlávek, Ph.D.; O. Aschermann Authors‘ workplace: II. interní klinika 1. LF UK a VFN, Praha Published in: Čas. Lék. čes. 2003; : 582-585 Category:
Direct PTCA is a treatment of choice in patients with acute myocardial infarction with ST segment elevations(STEMI). Fibrinolysis remains important modality of treatment in these patients. Currently, there are more then 100 tissueplasminogen activator mutants available with different fibrin specificity. In a clinical practice, tissue-type plasminogenactivator (t-PA), recombinant tissue-type plasminogen activator (rt-PA), tenecteplase (TNK-tPA) and lanoteplase(n-PA) are most important examples. Fibrinolytic treatment in STEMI patients should be used in patients presenting infirst 4 hours after beginning of chest pain, when it is sure, that direct PTCA cannot be started within next 90 minutes.Concomittant therapy of acute STEMI patients consists of anticoagulans, antiplatelet and antiagregatory treatment.
Key words: acute myocardial infarction, fibrinolysis, tissue-type plasminogen activator.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
